Table 2.
Prevalence and relevance of different urogenital pathogens in relation to hrHPV status.
| Cohort | hrHPV positive | hrHPV negative | Chi-square test | |
|---|---|---|---|---|
| Bacterial vaginosis | 27.2% (270/992) | 36.6% (180/492) | 18.0% (90/500) | p < 0.001 |
| Chlamydia trachomatis | 1.9% (19/992) | 3.4% (17/492) | 0.4% (2/500) | p < 0.001 |
| Neisseria gonorrhoeae | 0.0% (0/992) | 0.0% (0/492) | 0.0% (0/500) | ND |
| Mycoplasma genitalium | 1.7% (17/992) | 3.0% (15/492) | 0.4% (2/500) | p < 0.001 |
| Candida spp. | 5.4% (53/990) | 5.9% (29/490) | 4.8% (24/500) | p = 0.434 |
| Candida glabrata | 1.,4% (14/990) | 1.0% (5/490) | 1.8% (9/500) | p = 0.299 |
| Trichomonas vaginalis | 0.1% (1/990) | 0.1% (1/490) | 0.0% (0/500) | p = 0.312 |
Chi-square test was performed to analyze if there were significant differences between groups.
ND, not determined; Candida spp., C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis.